



Press Release

Thursday, April 19, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR CISPLATIN INJECTION

April 19, 2012 Bangalore: Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received US FDA approvals for ***Cisplatin Injection, 1 mg/mL packages in 50 mL and 100 mL Multiple Dose Vials.***

Cisplatin is amongst the products in the drug shortage list of US FDA. According to IMS data, the US market for generic Cisplatin is approximately USD 10 Million.


Cisplatin is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.

About Cisplatin

Cisplatin is a chemotherapy drug. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors.

About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, penicillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest sterile capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.



About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 13 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)	Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
	Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in

